Navigation Links
Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase the Maximal Steady State Subcutaneous Bioavailability from 64% to 100% -

SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that final results of the Enhanze(TM) Technology clinical trial demonstrating improved absorption and bioavailability of a representative commercially-available large protein molecule therapeutic (LPMT) were presented at the 34th Annual Meeting of the Controlled Release Society in Long Beach, California. Enhanze Technology is Halozyme's enzyme-based drug delivery platform based on recombinant human PH20 hyaluronidase (rHuPH20). The abstract describing this trial was rated by the Controlled Release Society as having notable high scientific quality and was designated for a podium presentation, which included a recently completed modeled population pharmacokinetic (PK) analysis used to estimate the effect of steady state co-administration of rHuPH20 with the LPMT.

This clinical trial, sponsored and funded solely by Halozyme, compared the PK, safety, and tolerability of an LPMT agent subcutaneously (SC) injected first without Enhanze Technology (rHuPH20) and then with rHuPH20 in 15 patients. The representative LPMT selected for this trial was HUMIRA(R) (adalimumab), based on the product being readily commercially available, well-recognized, labeled for SC route of administration, and for which a validated assay for PK profiling could be developed. The open-label cross-over study used escalating doses of rHuPH20 (ranging from 1,600 U to 12,800 U) and a fixed dose of HUMIRA (40 mg) injected every two weeks. Patients with rheumatoid arthritis on maintenance HUMIRA were crossed-over to a single SC injection of HUMIRA co-injected with rHuPH20, and the two injections were compared with regard to PK and s
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
7. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Data Reviewed in End of Phase 2a Meeting , ... (Nasdaq: VIAP ), a biotechnology company focused on ... metabolic disease, announced today that an end of Phase 2a ... held with the U.S. Food and Drug Administration (FDA). ...
... New Capabilities Will Further Extend GeneXpert System Technology Advantages , ... CPHD ) today announced that it has received a ... and Infectious Diseases to develop new ten-color detection technology for ... be awarded to Cepheid and the University of Medicine ...
Cached Medicine Technology:VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 2Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 3Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 4
(Date:8/31/2014)... Sunday 31 August 2014: Mortality and morbidity ... year despite good use of oral anticoagulants, according to ... General Pilot Registry. The findings were presented for the ... chairperson Professor Gregory Lip (Birmingham, UK). , Professor Lip ... focused on management practices of European cardiologists conducted since ...
(Date:8/30/2014)... August 2014: A new batteryless cardiac pacemaker based ... motion was presented at ESC Congress 2014 today ... does not require battery replacement. , Mr Zurbuchen, ... at ARTORG, University of Bern, Switzerland, said: "Batteries ... Once they reach a critically low energy level, ...
(Date:8/30/2014)... In a world where a typical response to conflict is ... a game app to teach another way. Launched in ... is a colorful way to encourage moral values playfully. ... double-duty by teaching players new ways to find happiness and ... for consistently taking the high road, the Ultimate Karma game ...
(Date:8/30/2014)... August 31, 2014 Atlanta based automotive ... to help raise money and awareness for ALS by ... General Managers, staff, and even Vice President Jimmy Ellis ... film and can be viewed on their Youtube page; ... the challenge, general managers and staff also took the ...
(Date:8/30/2014)... 30, 2014 The Truth about Six Pack ... will reveal to users some shocking foods that can burn ... in modeling looks, as well as some motivation secrets for ... that there is one unique trick that can help users ... despite what many people might think, cardio exercise routines are ...
Breaking Medicine News(10 mins):Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:Newly Launched Ultimate Karma App Elicits Happiness in Players and Encourages Moral Values 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2
... age, they,often become forgetful and unsteady and may have ... need help recovering from an,injury or illness. Many don,t ... the familiar surroundings of home. The dilemma children,then face ... cared for without,placing them in an assisted living facility. ...
... to Play a Key Role as Governments and Civil Society ... Region Ponder Urgent Strategies to Tackle the Crisis, ... -- On World AIDS Day 2007, hundreds, perhaps thousands, of ... HIV in cities across,the Asia Pacific, becoming the latest statistics ...
... hip arthroplasty (THA), or hip replacement, is an ... have only followed patients for up to one ... issue of Arthritis Care & Research ( http://www.interscience.wiley.com/journal/arthritiscare ... years following hip replacement and found a long-term ...
... SAN FRANCISCO, Nov. 28 ECO2 Plastics, Inc.,(OTC ... eco-friendly,recycling company that is changing the way plastics ... that the Company,s,proprietary cleaning process can produce PET ... the manufacturing of food-contact containers., "Based upon ...
... Conseco, Inc. (NYSE:,CNO) said today that it has agreed to ... Group, Inc. (LTCG) for certain,back-office functions of the long term ... earlier this year that it was,considering this solution. Under the ... the customer call center and the ...
... -- There are estimated to be between ... with chronic Immune Thrombocytopenic Purpura (ITP), an autoimmune ... in their blood -- causing bruises, nosebleeds and, ... an international multicenter clinical research study led by ...
Cached Medicine News:Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 2Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 2Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 4Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 5Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 6Health News:Long-term improvement seen with hip replacement 2Health News:ECO2 Plastics to File for FDA Approval for Food-Contact Applications 2Health News:ECO2 Plastics to File for FDA Approval for Food-Contact Applications 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 4Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 5Health News:Eltrombopag studied in Idiopathic Thrombocytopenic Purpura 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... Hoffmann® II Hybrid External Fixation System ... generation in hybrid fixation. It incorporates ... and is designed to offer speed ... patented Hoffmann® snap-fit technology. , ,Using ...
Medicine Products: